Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Benitec Biopharma (BNTC) over the last 6 years, with Q2 2025 value amounting to $29000.0.

  • Benitec Biopharma's Change in Receivables fell 8352.27% to $29000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$197000.0, marking a year-over-year decrease of 21193.18%. This contributed to the annual value of -$197000.0 for FY2025, which is 21193.18% down from last year.
  • Latest data reveals that Benitec Biopharma reported Change in Receivables of $29000.0 as of Q2 2025, which was down 8352.27% from -$226000.0 recorded in Q3 2024.
  • Benitec Biopharma's 5-year Change in Receivables high stood at $176000.0 for Q2 2024, and its period low was -$226000.0 during Q3 2024.
  • For the 4-year period, Benitec Biopharma's Change in Receivables averaged around -$3142.9, with its median value being $7000.0 (2021).
  • Over the last 5 years, Benitec Biopharma's Change in Receivables had its largest YoY gain of 75714.29% in 2022, and its largest YoY loss of 77142.86% in 2022.
  • Quarter analysis of 4 years shows Benitec Biopharma's Change in Receivables stood at -$7000.0 in 2021, then surged by 757.14% to $46000.0 in 2022, then plummeted by 591.3% to -$226000.0 in 2024, then skyrocketed by 112.83% to $29000.0 in 2025.
  • Its Change in Receivables was $29000.0 in Q2 2025, compared to -$226000.0 in Q3 2024 and $176000.0 in Q2 2024.